COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 304

Article download: 153

IP Indian Journal of Clinical and Experimental Dermatology

Bilastine for the treatment of chronic spontaneous urticaria: Consensus statement for Indian patients

Full Text PDF Share on Facebook Share on Twitter

Review Article

Author Details : Kiran Godse*, Abhishek De, Vijay Zawar, Bela Shah, Mukesh Girdhar

Volume : 5, Issue : 3, Year : 2019

Article Page : 180-185

Suggest article by email


Urticaria or hives is a common skin condition that affects population with a lifetime prevalence of up
to 22% and point prevalence of 1%. Antihistamines play a very important role in the treatment of
chronic urticaria. International guidelines recommend second-generation, non-sedating H1-antihistamines
as the first line therapy for management of chronic urticaria. Uncontrolled symptoms in many patients
demand a new antihistamine which offers significant efficacy without or with minimal adverse events
especially sedation. Bilastine, a second generation H1-antihistamine, offers significant benefits over most
antihistamines including once daily dosage, significant efficacy in relieving symptom, minimal risk of
drug to drug interactions and adverse events. This consensus statement is prepared to discuss the role of
bilastine in the management of chronic urticaria among Indian patients. Comprehensive review of published
literature was done to prepare a draft of consensus statement. The draft was circulated to the experts for
their review and comments. Final document was prepared with incorporation of their comments.

Keywords: Bilastine, C hronic urticaria, Consensus statement.

Doi : 10.18231/j.ijced.2019.039

How to cite : Godse K, Abhishek De, Zawar V, Shah B, Girdhar M, Bilastine for the treatment of chronic spontaneous urticaria: Consensus statement for Indian patients. IP Indian J Clin Exp Dermatol 2019;5(3):180-185

Copyright © 2019 by author(s) and IP Indian J Clin Exp Dermatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (